Page last updated: 2024-08-05 11:08:44
organic phosphate
null
ChEBI ID: 25703
Members (8)
| Member | Definition | Role |
|---|---|---|
| baeocystin | A tryptamine alkaloid that is N-methyltryptamine carrying an additional phosphoryloxy substituent at position 4. | baeocystin |
| benphothiamine | A thioester that is a synthetic analogue of thiamine obtained by acylative cleavage of the thiazole ring and O-phospohorylation. | benfotiamine |
| carboxy phosphate | An acyclic mixed acid anhydride formed by condensation of phosphoric acid with carbonic acid. | carboxyphosphoric acid |
| chlorfenvinphos | chlorfenvinfos | |
| diazoxon | An organic phosphate that is diethyl hydrogen phosphate in which the hydrogen of the hydroxy group has been replaced by a 6-methyl-2-(propan-2-yl)pyrimidin-4-yl group. It is a metabolite of the pesticide diazinon. | diazoxon |
| psilocybin | A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional phosphoryloxy substituent at position 4. The major hallucinogenic alkaloid isolated from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms"). | psilocybin |
| pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid | An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6. | 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid |
| VPC 23019 | A secondary carboxamide resulting from the formal condensation of the carboxy group of O-phospho-D-serine with the amino group of m-octylaniline. An analogue of sphingosine-1-phosphate (S1P), it is a potent antagonist for both S1P1 and S1P3 receptors. It can inhibit S1P-induced migration of thyroid cancer cells, ovarian cancer cells, and neural stem cells. | VPC 23019 |
Research
Studies (2,099)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 451 (21.49) | 18.7374 |
| 1990's | 228 (10.86) | 18.2507 |
| 2000's | 540 (25.73) | 29.6817 |
| 2010's | 421 (20.06) | 24.3611 |
| 2020's | 459 (21.87) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 151 (6.77%) | 5.53% |
| Reviews | 268 (12.02%) | 6.00% |
| Case Studies | 55 (2.47%) | 4.05% |
| Observational | 6 (0.27%) | 0.25% |
| Other | 1,750 (78.48%) | 84.16% |